METFORMIN EFFECTS ON NEUREGULIN-1 IN POLYCYSTIC OVARIAN WOMEN

The study aims to assess the levels of Neuregulin 1 (NRG1) in patients with Polycystic Ovary Syndrome (PCOS) and to determine the impact of metformin treatment on their serum NRG1 levels. PCOS is a common endocrine disorder in women of reproductive age, while NRG1 is linked to regulating inflammation and ovulation. The study was conducted on sixty women with PCOS and thirty healthy women as the control group. Thirty patients completed the follow-up study and continued on metformin treatment for three months. The study was a cross-sectional study done in Salah Al-Deen general hospital/gynaecology and obstetrics department in Tikrit City from November 2022 to January 2023. The participants were diagnosed with PCOs based on the Rotterdam criteria, and their BMI and insulin resistance were measured before and after therapy. Fasting serum NRG1 was also measured. The study found that women with PCOS had increased levels of fasting blood glucose, insulin, and insulin resistance, as well as increased levels of NRG1. However, treatment with metformin for three months resulted in a significant decrease in body mass index, blood glucose, insulin, and insulin resistance. NRG1 level decreased significantly after 3 months of treatment with 850 mg per day with metformin in women with PCOS.